[go: up one dir, main page]

WO2007000347A3 - Composes modulant le recepteur de vegf et utilisation de ceux-ci - Google Patents

Composes modulant le recepteur de vegf et utilisation de ceux-ci Download PDF

Info

Publication number
WO2007000347A3
WO2007000347A3 PCT/EP2006/006314 EP2006006314W WO2007000347A3 WO 2007000347 A3 WO2007000347 A3 WO 2007000347A3 EP 2006006314 W EP2006006314 W EP 2006006314W WO 2007000347 A3 WO2007000347 A3 WO 2007000347A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
agonistic
therapy
binding region
peptide mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/006314
Other languages
English (en)
Other versions
WO2007000347A2 (fr
Inventor
Andrea Luca Domenico D
Carlo Pedone
Bruno Trimarco
Guido Iaccarino
Maria Caterina Turco
Arturo Leone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROSELLI PATRIZIA
Original Assignee
ROSELLI PATRIZIA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROSELLI PATRIZIA filed Critical ROSELLI PATRIZIA
Priority to US11/988,094 priority Critical patent/US20090305994A1/en
Priority to JP2008518723A priority patent/JP2008546821A/ja
Priority to EP06754625A priority patent/EP1926494A2/fr
Priority to CA002614358A priority patent/CA2614358A1/fr
Publication of WO2007000347A2 publication Critical patent/WO2007000347A2/fr
Publication of WO2007000347A3 publication Critical patent/WO2007000347A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation de composés se liant aux récepteurs du facteur de croissance endothélial vasculaire et modulant la réponse angiogénique. Ces composés, qui imitent la région 17-25 de l'acide aminé de VEGF impliquée dans la reconnaissance du récepteur de façon à inhiber ou stimuler le processus angiogénique, peuvent être utilisés pour traiter des maladies caractérisées par une angiogenèse VEGF-dépendante excessive ou déficiente, telles que l'ischémie chronique, le cancer, la rétinopathie proliférative et l'arthrite rhumatoïde, ainsi que des états pathologiques ou des affections bénéficiant de la formation ou de la régénérescence de nouveaux vaisseaux. Ils peuvent également être utilisés dans le diagnostic de pathologies caractérisées par une surexpression des récepteurs de VEGF, ou comme outils biochimiques destinés à analyser les voies cellulaires dépendantes de l'activation du récepteur de VEGF.
PCT/EP2006/006314 2005-06-29 2006-06-29 Composes modulant le recepteur de vegf et utilisation de ceux-ci Ceased WO2007000347A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/988,094 US20090305994A1 (en) 2005-06-29 2006-06-29 Compounds Modulating Vegf Receptor and Uses Thereof
JP2008518723A JP2008546821A (ja) 2005-06-29 2006-06-29 Ｖｅｇｆ受容体を制御する化合物、およびその使用
EP06754625A EP1926494A2 (fr) 2005-06-29 2006-06-29 Composes modulant le recepteur de vegf et utilisation de ceux-ci
CA002614358A CA2614358A1 (fr) 2005-06-29 2006-06-29 Composes modulant le recepteur de vegf et utilisation de ceux-ci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69467105P 2005-06-29 2005-06-29
US60/694,671 2005-06-29

Publications (2)

Publication Number Publication Date
WO2007000347A2 WO2007000347A2 (fr) 2007-01-04
WO2007000347A3 true WO2007000347A3 (fr) 2007-07-19

Family

ID=37595492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006314 Ceased WO2007000347A2 (fr) 2005-06-29 2006-06-29 Composes modulant le recepteur de vegf et utilisation de ceux-ci

Country Status (5)

Country Link
US (1) US20090305994A1 (fr)
EP (1) EP1926494A2 (fr)
JP (1) JP2008546821A (fr)
CA (1) CA2614358A1 (fr)
WO (1) WO2007000347A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657078T3 (es) * 2011-06-01 2018-03-01 Universität Heidelberg Agente activador de VEGFR2/3 para uso en el tratamiento de disfunciones cognitivas
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
WO2014185540A1 (fr) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarqueurs pour prédire et évaluer la réponse de sujets atteints de cancer de l'endomètre à des composés à base de lenvatinib
US9526762B1 (en) 2013-08-09 2016-12-27 William Marsh Rice University Multidomain peptides for promoting angiogenesis
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
KR20250024102A (ko) 2015-02-25 2025-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
WO2019195780A1 (fr) 2018-04-05 2019-10-10 The Regents Of The University Of California Mimétiques de protéoglycane pour une cicatrisation, une angiogenèse et une réparation vasculaire améliorées

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D'ANDREA L D: "TARGETING VEGF RECEPTORS USING DESIGNED POLYPEPTIDES", PEPTIDES 2002. PROCEEDINGS OF THE EUROPEAN PEPTIDE SYMPOSIUM, XX, XX, EDIZIONI ZIINO, EDS. BENEDETTI E., PEDONE C., 2002, Napoli, Italy, pages 454 - 455, XP009082477 *
D'ANDREA LUCA DOMENICO ET AL: "Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 40, 26 September 2005 (2005-09-26), pages 14215 - 14220, XP002430308, ISSN: 0027-8424 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same

Also Published As

Publication number Publication date
CA2614358A1 (fr) 2007-01-04
EP1926494A2 (fr) 2008-06-04
US20090305994A1 (en) 2009-12-10
WO2007000347A2 (fr) 2007-01-04
JP2008546821A (ja) 2008-12-25

Similar Documents

Publication Publication Date Title
WO2007000347A3 (fr) Composes modulant le recepteur de vegf et utilisation de ceux-ci
WO2006074428A3 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
WO2013184960A3 (fr) Protéines chimères du facteur de croissance des fibroblastes 23 et méthodes d'utilisation
WO2008105797A3 (fr) Polynucléotides codant pour de nouveaux variants du pcsk9
WO2006062685A3 (fr) Nouveaux peptides se liant au recepteur de l'erythropoietine
PL2005185T3 (pl) Sposoby identyfikowania celów polipeptydowych
EP4342995A3 (fr) Procédés de régulation de la pharmacocinétique sanguine d'anticorps
WO2007143168A3 (fr) Anticorps dirigés contre le récepteur de l'il-6 humaine, à affinité élevée pour ledit récepteur
PL1869085T3 (pl) Nowe przeciwciało anty-PIGF
WO2004101606A3 (fr) Nouveaux peptides se fixant au recepteur de l'erythropoietine
WO2009019531A3 (fr) Peptides bioactifs et leur procédé d'utilisation
WO2010036630A3 (fr) Composés modulant sélectivement le récepteur cb2
WO2007144893A3 (fr) Anticorps bloquant l'activation du récepteur du facteur de croissance des fibroblastes et leurs procédés d'utilisation
WO2008009963A3 (fr) Dérivés de la pyrimidine
WO2006138343A3 (fr) Compositions comprenant des variants de proteine associee au recepteur (rap) specifiques a lrp2, et utilisations correspondantes
HK1198832A1 (en) Fn14 binding proteins and uses thereof
PL1972637T3 (pl) Antagoniści selektywni wobec huTNFR1
MX2012001278A (es) Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
ZA201001467B (en) Novel heterocyclic compounds as mglu5 antagonists
WO2008024979A3 (fr) Procédés d'utilisation de lysophospholipides de signalisation cellulaire
WO2004094476A3 (fr) Compositions et methodes se rapportant a stop-1
EP1867994A3 (fr) Ligand pour protéine G couplé au récepteur GPR72 et utilisations correspondantes
WO2005097826A3 (fr) Peptide de prokineticine 2beta et utilisation
PL1960427T3 (pl) Multimeryczne polipeptydy receptora Fc
DE502006006593D1 (de) Verfahren zum nachweis von autoimmunantikörpern gegen den tsh-rezeptor und neue tsh- rezeptorchimären

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2614358

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008518723

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006754625

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06754625

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006754625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11988094

Country of ref document: US